11-02/03 :: February / March 2011
nanotimes
Companies Facts
U
sing Fluidigm Corporation‘s BioMark™ System and Digital Array™ integrated fluidic circuits
(IFCs), researchers from the University of Califor- nia San Francisco (UCSF) have identified serum microRNAs that can serve as biomarkers for prostate cancer. To do this, the UCSF research group desi- gned their own microRNA preAMP and PCR primers specifically to be used on the BioMark platform. Through this method, they were able to identify mRNA signatures that correlate with prognosis.
One in six men will be diagnosed with prostrate cancer during their lifetime. Recent prostate speci- fic antigen (PSA) based screening trials indicate an urgent need for novel and non-invasive biomarker identification strategies to improve the prediction of prostate cancer behaviour. Non-coding microRNAs (miRNAs) in the serum and plasma have been shown to have potential as non-invasive markers for physio- logical and pathological conditions. To identify serum miRNAs that diagnose and correlate with prognosis of prostate cancer, the researchers at UCSF deve- loped a multiplex quantitative reverse transcription PCR (qRT-PCR) method involving purification of multiplex PCR products followed by uniplex analy- sis on a Fluidigm microfluidics chip to evaluate 384 human miRNAs. Using Dgcr8 and Dicer knockout (small RNA - deficient) mouse ES cells (mESC) as the benchmark, the researchers confirmed the validity of their technique, while uncovering a significant lack of accuracy in previously published methods. Profiling 48 sera from healthy men and untreated prostate cancer patients with differing CAPRA (Cancer of the Prostate Risk Assessment) scores, UCSF researchers identified miRNA signatures that allowed them to diagnose cancer patients and correlate with progno- sis. These serum signatures included oncogenic and
tumor suppressive miRNAs suggesting functional roles in prostate cancer progression.
Furthermore, Fluidigm has announced that MLL Mu- nich Leukemia Laboratory has used the company‘s Access Array™ technology to help it uncover mu- tations in over 80% of chronic myelomonocytic leukemia (CMML) patients, providing new insights into the molecular heterogeneity of the disease. MLL researchers applied the unique properties of the Fluidigm Access Array System to prepare the samples and barcode the amplicons for next-generation deep-sequencing using 454 sequencing technology.
http://urology.ucsf.edu/blellochlab/protocols.htm http://www.fluidigm.com http://www.mll.com
H
eadwaters Incorporated (NYSE: HW) has com- menced a cash tender offer (the “Tender Offer”)
for any and all of its outstanding 11-3/8% Senior Secured Notes due 2014 (CUSIP No. 42210PAN2) (the “Notes”). As of February 15, 2011, there was approximately $328.3 million aggregate principal amount of Notes outstanding.
29
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95